Certified by Founder Lodge
Myricx Bio
United Kingdom - London
START UP
1 Disclosed Funding Rounds $115,246,800
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| July, 09 ,2024 | Series A | $115,246,800 |
Eli Lilly and Company
Novo Holdings
British Patient Capital
Abingworth
Sofinnova Partners
Brandon Capital
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Standard Bots | $63,000,000 | (Jul 16, 2024)
Coldcart | $6,500,000 | (Jul 16, 2024)
Modicus Prime | $3,500,000 | (Jul 16, 2024)
Jacobi Robotics | $5,000,000 | (Jul 16, 2024)
Neuspera Medical Inc. | $23,000,000 | (Jul 16, 2024)
